Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Pain Therapeutics, Inc. (NasdaqNM:PTIE)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials | Reports
Recent Events
Aug  9Earnings Announcement
Location
416 Browning Way
South San Francisco, CA 94080
Phone: (650) 624-8200
Fax: (650) 624-8222
Employees (last reported count): 26
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 61%
·Institutional: 35% (89% of float)
(60 institutions)
·Net Inst. Buying: 196.0K shares (+2.07%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Pain Therapeutics, Inc. is developing a new generation of opioid painkillers with improved clinical benefits. The Company uses its technology to reformulate existing opioid painkillers into new drugs, which it believes offer enhanced pain relief, fewer adverse side effects and reduced tolerance and addiction compared to existing opioid painkillers. If approved by the Food and Drug Administration (FDA) the Company believes its proprietary drugs could replace many existing opioid painkillers commonly used to treat moderate to severe pain. The Company believes its products may encounter fewer clinical and regulatory hurdles than new chemical entities, because they consist of drugs that, individually, are already FDA approved. The Company product candidates include PTI-555: Oral Morphine/Low-Dose Naltrexone, PTI-501: Injectable Morphine/Low-Dose Naloxone, PTI-601: Tramadol/Low-Dose Naltrexone, and PTI-701: Hydrocodone/Low-Dose Naltrexone, and PTI-801: Oxycodone/Low-Dose Naltrexone.
More from Market Guide: Expanded Business Description

Financial Summary
Pain Therapeutics, Inc. is a development stage company that is developing a new generation of opioid painkillers by reformulating opioid drugs to improve clinical results and reduce side effects. For the six months ended 6/01, the company reported no revenues. Net loss applicable to Common decreased 78% to $5.3 million. Lower loss reflects the absence of $14.2 million for the beneficial conversion of Preferred stock.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Remi Barbier, 41
Chairman, Pres, CEO
$368K--  
David Johnson, 47
CFO
203K$2.8M
Barry Sherman, M.D., 59
Exec. VP and CMO
266K1.2M
Michael O' Donnell, 42
Sec., Director
--  --  
Edmon Jennings, 54
CCO
200K260K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:PTIEAs of 31-Aug-2001
Price and Volume
52-Week Low
on 14-June-2001
$5.40 
Recent Price$8.10 
52-Week High
on 7-Sep-2000
$24.00 
Daily Volume (3-month avg)60.1K
Daily Volume (10-day avg)16.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-58.1%
52-Week Change
relative to S&P500
-43.7%
Share-Related Items
Market Capitalization$217.1M
Shares Outstanding26.8M
Float10.5M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$2.72 
Earnings (ttm)-$0.56 
Earnings (mrq)-$0.12 
SalesN/A 
Cash (mrq)$2.67 
Valuation Ratios
Price/Book (mrq)2.97 
Price/EarningsN/A 
Price/SalesN/A 
Income Statements
Sales (ttm)$0 
EBITDA (ttm)-$14.6M
Income available to common (ttm)-$13.4M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-19.85%
Return on Equity (ttm)-21.96%
Financial Strength
Current Ratio (mrq)48.40 
Debt/Equity (mrq)0 
Total Cash (mrq)$71.6M
Short Interest
As of 8-Aug-2001
Shares Short52.0K
Percent of Float0.5%
Shares Short
(Prior Month)
81.0K
Short Ratio0.80 
Daily Volume65.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.